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Significant Inhibition of Corneal Scarring In Vivo with
Tissue-Selective, Targeted AAV5 Decorin Gene Therapy
Rajiv R. Mohan,1,2,3 Ashish Tandon,1,2 Ajay Sharma,1,2 John W. Cowden,2
and Jonathan C. K. Tovey1,2
PURPOSE. This study tested a hypothesis that tissue-selective
targeted decorin gene therapy delivered to the stroma with
adeno-associated virus serotype 5 (AAV5) inhibits corneal fi-
brosis in vivo without significant side effects.
METHODS. An in vivo rabbit model of corneal fibrosis was used.
Targeted decorin gene therapy was delivered to the rabbit
cornea by a single topical application of AAV5 (100 L; 6.5 
1012 g/mL) onto the bare stroma for 2 minutes. The levels of
corneal fibrosis were determined with stereomicroscopy, slit
lamp biomicroscopy, -smooth muscle actin (SMA), fibronec-
tin, and F-actin immunocytochemistry, and/or immunoblot-
ting. CD11b, F4/80 immunocytochemistry, and TUNEL assay
were used to examine immunogenicity and cytotoxicity of
AAV5 to the cornea. Transmission electron microscopy (TEM)
was used to investigate ultrastructural features. Slot-blot–quan-
tified the copy number of AAV5-delivered decorin genes.
RESULTS. Selective decorin delivery into the stroma showed a
significant (P  0.01) decrease in corneal haze (1.3  0.3)
compared with the no-decorin-delivered control rabbit corneas
(3  0.4) quantified using slit lamp biomicroscopy. Immuno-
staining and immunoblot analyses detected significantly re-
duced levels of SMA, F-actin, and fibronectin proteins (59%–
73%; P  0.001 or 0.01) in decorin-delivered rabbit corneas
compared with the no-decorin-delivered controls. The visual
clinical eye examination, slit lamp clinical studies, TUNEL,
CD11b, and F4/80 assays revealed that AAV5-mediated decorin
gene therapy is nonimmunogenic and nontoxic for the cornea.
TEM studies suggested that decorin gene delivery does not
jeopardize collagen fibrillogenesis as no significant differences
in collagen fibril diameter and arrangement were observed in
decorin-delivered and no-decorin-delivered control corneas.
CONCLUSIONS. Tissue-targeted AAV5-mediated decorin gene
therapy is effective and safe for treating corneal fibrosis in vivo.
(Invest Ophthalmol Vis Sci. 2011;52:4833–4841) DOI:
10.1167/iovs.11-7357
Corneal scarring is the third leading cause of global blind-ness and affects 1.3 million Americans every year.1,2 The
corneal blinding disorders have a great cumulative socioeco-
nomic impact on society. A variety of factors, such as infection,
trauma, and chemical and mechanical injury to the eye have
been shown to cause fibrosis or scarring in the cornea.3–5
Among the most common eye surgeries, photorefractive kera-
tectomy (PRK) has been implicated in the corneal haze that
occurs in a significant portion of patients with high myopia due
to epithelial injury and abnormal wound healing in the cornea
after excimer laser utilization.6,7 Nevertheless, PRK is a very
safe and precise laser eye treatment among the laser eye sur-
geries currently available for vision correction.7 The current
conventional drug therapies for treating corneal scarring re-
quire repeated applications, provide short-term benefit, cause
many side effects, and are often ineffective in eliminating
corneal scarring. At present, no efficacious, long-term treat-
ments for curing corneal scarring without causing side effects
are available. Corneal transplantation is a viable treatment for
the restoration of vision in patients with severe corneal scar-
ring.
Gene therapy is an attractive approach for the treatment of
ocular surface disorders such as corneal scarring.8–13 The cor-
nea is an ideal organ for gene therapy because of its immune-
privileged status and accessibility for treatment with gene
therapy reagents and visual monitoring. Various viral and non-
viral vectors have been tested for delivering genes to the
cornea.8–13 The proof of concept for treating corneal scarring
with gene therapy has been demonstrated by delivering the
herpes simplex virus thymidine kinase gene with retroviral
vector after keratectomy, followed by topical application of
ganciclovir in a PRK-induced corneal fibrosis rabbit model.14,15
Despite the gene therapy promise shown by this study for
treating corneal disorders, not much progress has been made.
Among viral gene therapy vectors, retrovirus and adenovirus
have been shown to cause multiple side effects that raise safety
concerns and sharply limit their clinical application. The ad-
eno-associated virus (AAV) vectors are highly efficient in trans-
ducing corneal cells that are nonpathogenic to patients and
safe for the environment. Recently, we found the AAV sero-
types 5, 8, and 9, among many tested AAV serotypes, to be
highly efficient and safe for delivering foreign genes into ro-
dent, rabbit, equine, and human cornea in vitro and in
vivo.11,12 Other investigators have found AAV vectors effective
for delivering genes to the cornea.16,17 Using a green fluores-
cent protein marker gene, we optimized site-selective, tissue-
targeted controlled gene transfer approaches for delivering
therapeutic genes into the stroma of the normal and damaged
(hazy and neovascularized) rabbit cornea in vivo, employing a
combination of AAV5 and custom vector-delivery tech-
niques.18,19 No apparent side effects were observed in the
rabbit eye. Our recent findings and the available literature
prompted to hypothesize that AAV-mediated targeted delivery
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of antifibrotic genes in the stroma can effectively treat corneal
fibrosis without causing significant side effects.
The molecular mechanism of corneal fibrosis has been ex-
tensively studied, but is still not fully defined. Scores of studies
suggest the role of numerous growth factors and cytokines in
the pathophysiology of corneal scarring.20,21 Of many cyto-
kines, transforming growth factor (TGF)-, released from cor-
neal epithelium after eye injury, has been demonstrated to play
a central role in the genesis of corneal fibrosis by promoting
myofibroblast formation, as well as synthesis of extracellular
matrix (ECM) and cytoskeletal proteins.19–21 The most con-
vincing support to this notion was provided by the ground-
breaking studies performed by Jester et al.21 that showed
significant inhibition of corneal fibrosis in rabbit eyes by topi-
cal application of TGF neutralizing antibodies. Thus, we hy-
pothesized that targeted delivery of TGF-antagonizing genes
in the cornea is a novel approach for treating corneal fibrosis.
Decorin, a small, leucine-rich proteoglycan, has been
shown to inhibit all three isoforms of TGF—TGF1, -2, and
-3—with equal efficiency.22–24 Numerous studies have dem-
onstrated the pivotal role decorin plays in suppressing TGF-
regulated fibrosis in the kidneys, lungs, skin, and periodontal
ligaments in vivo and in vitro.25–32 Recently, we demonstrated
that decorin overexpression in human corneal fibroblasts sig-
nificantly prevents their transformation to myofibroblasts and
reduces expression of profibrotic genes when grown in the
presence of TGF1 in serum-free conditions.33 This study led
us to hypothesize that tissue-selective, targeted decorin gene
therapy delivered to the stroma with AAV can retard corneal
scarring in vivo without causing side effects. In this study, we
tested the efficacy and safety of decorin gene therapy with
AAV5 in a laser-induced corneal fibrosis model.
MATERIALS AND METHODS
Animals
Twenty-four female New Zealand White rabbits (Myrtle Laboratories
Inc., Thompson’s Station, TN) weighing 2.5 to 3.0 kg were used in this
study. The Institutional Animal Care and Use Committee of the Uni-
versity of Missouri-Columbia and Harry S. Truman Memorial Veterans’
Hospital, approved the study. All animals were treated in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. The rabbits were anesthetized by intramuscular in-
jection of a mixture of ketamine hydrochloride (50 mg/kg) and xyla-
zine hydrochloride (10 mg/kg). In addition, topical ophthalmic 0.5%
proparacaine hydrochloride (Alcon, Fort Worth, TX) was used for local
anesthesia.
Corneal Fibrosis in Rabbit Eyes
A well-established PRK technique was used to produce fibrosis in the
rabbit cornea.34 In all 24 rabbits, corneal haze was induced in one eye,
and the contralateral eye served as a naïve or PRK-untreated control. In
an anesthetized rabbit, 2 to 3 drops of proparacaine hydrochloride
solution were instilled on the cornea, and a wire lid speculum was
inserted to expose the corneal surface. The corneal epithelium was
removed by gentle scraping with a no. 64 Beaver blade (BD Biosci-
ences, Franklin Lakes, NJ), and PRK was performed by creating a 6-mm
ablation zone to 9 D with the excimer laser (Summit Apex; Alcon),
to produce fibrosis in the cornea, as reported previously.34 This PRK
technique has been shown to consistently produce fibrosis and myo-
fibroblasts in the rabbit cornea that peaks at 4 weeks.34
AAV-Decorin Plasmid Generation and
Titer Production
The decorin gene was PCR-amplified from rabbit corneal fibroblast
cDNA using forward (5GAT CGC GGC CGC AAT CAT GAC GGC AAC
TCT CAT C3) and reverse (5GTC AGC GGC CGC GAG TTA CTT GTA
GTT TCC GAG C3) primers. The amplified PCR product was cloned
into the AAV2 plasmid pTRUF11, containing a hybrid promoter (cyto-
megalovirus enhancer and chicken -actin) and the simian virus 40
polyadenylation site, using the NotI site. The resultant decorin-cloned
plasmid was packaged into AAV5 with a two-plasmid co-transfection
method reported previously.35 In brief, approximately 1  109 HEK
293 cells were cultured in Dulbecco’s modified Eagle’s medium (Hy-
clone Laboratories, Inc., Logan, UT), supplemented with 5% fetal
bovine serum and antibiotics. A CaPO4 transfection method was used
by mixing an equimolar ratio (1:1) of decorin-cloned AAV2 plasmid and
AAV5 rep-cap helper plasmid. This precipitate was applied to the cell
monolayer, and the transfection was allowed to incubate at 37°C in 7%
CO2 for 60 hours. The cells were then harvested, lysed by freeze–thaw
cycles, and subjected to discontinuous iodixanol gradient centrifuga-
tion at 350,000g for 1 hour. This iodixanol fraction was further purified
and concentrated by column chromatography on a 5-mL Sepharose
column on an FPLC system (HiTrap Q column on a model AKTA
system; GE Healthcare, Piscataway, NJ). The vector was eluted from
the column using 215 mM NaCl buffer (pH 8.0), and the rAAV peak
was collected. The AAV5 decorin (AAV5-dcn) vector-containing frac-
tion was then concentrated and the buffer exchanged in balanced
saline (BSS; Alcon) with 0.014% Tween 20, using a concentrator (Bio-
max 100K; Millipore, Billerica, MA). The vector was titrated for DNase-
resistant vector genomes by real-time PCR, relative to a standard.
AAV5 Transduction to Rabbit Cornea
The rabbits were divided into two groups. Group I corneas were
exposed topically to 100 L decorin gene–expressing AAV5 titer
(6.5  1012 g /mL; n  12) for 2 minutes via a custom cloning
cylinder technique, as described recently immediately after PRK sur-
gery.18 Group II corneas received 100 L AAV5 titer (6.5  1012
g/mL) expressing the green fluorescent protein gene (n 12). The
contralateral naïve corneas served as PRK-untreated (n  12) and
AAV5-untreated (n  12) negative controls. For each group, slit lamp
biomicroscopy was performed in all 12 treated eyes before euthanati-
zation 4 weeks after PRK and vector application. After euthanatization,
the 12 corneal tissues were divided for the analyses as follows: 6 for
immunocytochemistry and microscopy, 2 for Western-blot, 2 for slot-
blot, and 2 for transmission electron microscopy.
Slit Lamp Biomicroscopy in Live Rabbits
The level of corneal haze and health in the eyes of live rabbits was
examined by visual clinical and slit lamp microscopic (BX 900 Slit
Lamp, Haag-Streit USA, Mason, OH) examinations before PRK and 4
weeks after PRK, as described earlier.34 Grade 0 was a completely clear
cornea; grade 0.5 had trace haze seen with careful oblique illumination
with the slit lamp biomicroscope; grade 1 was more prominent haze
not interfering with the visibility of fine iris details; grade 2 was mild
obscuration of iris details; grade 3 was moderate obscuration of the iris
and lens; and grade 4 was complete opacification of the stroma in the
area of ablation. Haze grading was performed in a masked manner.
Optical coherence tomography was performed with a high-definition
instrument (Cirrus 3000; Carl Zeiss Meditec, Dublin, CA) in live rabbits
under general anesthesia, to analyze corneal thickness. The scans with
the best signal strength were selected, and imaging data were analyzed
with the optical coherence tomography system software (Cirrus, ver.
3.0; Carl Zeiss Meditec).
Euthanatization and Tissue Collection
Four weeks after PRK and vector application, the rabbits were hu-
manely euthanatized with a pentobarbitone (150 mg/kg) overdose
while under general anesthesia. Corneas of six rabbits of each group
were removed with forceps and sharp Westcott scissors, embedded in
liquid optimal cutting temperature (OCT) compound (Sakura FineTek,
Torrance, CA) in a 24  24  5-mm mold (Fisher Scientific, Pittsburgh,
PA), and snap frozen, as reported earlier.34 Frozen tissue blocks were
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maintained at 80°C for future use. Tissue sections were cut 7 or 20
m thick with a cryostat (HM 525M; Microm GmbH, Walldorf, Ger-
many), placed on 25  75  1-mm microscope slides (Superfrost Plus;
Fisher Scientific), and maintained frozen at 80°C until staining. The
remaining six rabbit corneal tissues of each group were immediately
either frozen in liquid nitrogen for Western blot (n  2) and slot-blot
(n  2) analyses or were fixed in buffer for transmission electron
microscopy (n  2).
Immunofluorescence Studies
Immunofluorescence staining for -smooth muscle actin (SMA), a
marker for myofibroblasts, was performed with mouse monoclonal
primary SMA antibody (1:200 dilution, M0851; Dako, Carpinteria,
CA). Tissue sections were incubated with 2% bovine serum albumin for
30 minutes at room temperature and then with SMA monoclonal
antibody for 90 minutes. For detection of the primary antibody, the
sections were exposed to Alexa 488 goat anti-mouse IgG secondary
antibody (1:1000 dilution, A11001; Invitrogen Inc., Carlsbad, CA) for 1
hour. SMA-positive cells in six randomly selected, nonoverlapping,
full-thickness central corneal columns, extending from the anterior
stromal surface to the posterior stromal surface, were counted accord-
ing to a method reported elsewhere.34 The diameter of each column
was 400 magnification field.
Fibronectin immunostaining was performed by incubating the tis-
sue sections in goat polyclonal primary antibody (1:200 dilution,
sc6952; Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 90 minutes.
For primary antibody detection, the sections were exposed to Alexa
594 donkey anti-goat IgG secondary antibody (1:500 dilution, A11058;
Invitrogen) for 1 hour. F-actin staining was performed with Alexa594-
conjugated phallotoxin (A12381; Invitrogen). The tissues were incu-
bated at 1:100 dilution for 90 minutes followed by subsequent washing
with HEPES.
The possibility of immunologic reaction to AAV5-mediated decorin
gene therapy was examined by performing CD11b (BDB550282; BD
Pharmingen, San Jose, CA) and F4/80 (MCA497; Serotec, Raleigh, NC)
immunostaining in rabbit corneal sections using rat anti-mouse anti-
body. Tissue sections were incubated at room temperature with the
CD11b primary antibody at a 1:50 dilution in a 1 HEPES buffer
containing 5% BSA for 90 minutes, followed by goat anti-rat IgG
secondary antibody (Alexa Fluor 594; Invitrogen) at a 1:500 dilution for
60 minutes. After completion of immunostaining, tissue sections were
mounted in medium containing DAPI (Vectashield; Vector Laborato-
ries, Inc. Burlingame, CA), viewed, and photographed under a fluores-
cence microscope (Leica, Deerfield, IL) equipped with a digital camera
system (SpotCam RT KE; Diagnostic Instruments, Sterling, MI).
TUNEL Assay
A TUNEL assay was performed in acetone-fixed rabbit corneal sections
using a fluorescent detection assay (ApopTag; Millipore) that detects
apoptosis and, to a lesser extent, necrosis according to the manufac-
turer’s instructions. A positive control (4 hours after mechanical cor-
neal scrape) and a negative control (unwounded) were included in
each assay.
Immunoblot Analysis
Rabbit corneal tissues were lysed in RIPA protein lysis buffer contain-
ing protease inhibitor cocktail (Roche Applied Sciences, Indianapolis,
IN). Protein samples were prepared for electrophoresis by heating at
90°C for 2 minutes followed by centrifugation at 10,000g for 10
minutes. The samples were transferred onto polyvinylidene difluoride
(PVDF) membranes (iBlot apparatus; Invitrogen), and the proteins
were detected with the following primary antibodies: SMA (mouse
monoclonal, 1:200 dilution; Dako) and -actin primary antibody (sc-
69879; Santa Cruz) followed by alkaline phosphatase–conjugated anti-
mouse secondary antibody (Fisher Scientific). After the membrane was
washed three times in 0.05% Tween-20 in Tris-buffered saline (pH 8.0)
for 5 minutes each, the blot was developed using the nitroblue tetra-
zolium (NBT)/5-bromo-4-chloro-3-indolylphosphate (BCIP) method.
Transmission Electron Microscopy
Rabbit corneas were fixed in a 2% glutaraldehyde and 2% paraformal-
dehyde solution in 0.1 M Na-cacodylate buffer (pH 7.4), postfixed in
1% osmium tetroxide, sequentially dehydrated in ethanol, and transi-
tionally dehydrated in acetone, followed by infiltration with an Epon
and Araldite (Electron Microscopy Sciences, Hatfield, PA) resin mix-
ture. The embedded cornea samples were sectioned at 85-nm on an
ultramicrotome (Ultracut UCT; Leica) and transferred onto a 200-mesh
copper grid for poststaining with uranyl acetate and Sato’s triple lead
stain. The samples were then imaged by transmission electron micro-
scope (1400; JEOL Tokyo, Japan).
Slot-Blot Analysis to Determine Gene
Copy Number
The copies of delivered plasmid were determined with slot-blot anal-
ysis. The frozen corneal tissues were ground in liquid nitrogen, and
DNA was isolated (DNA Easy kit; Qiagen, Valencia, CA). The standards
were prepared using 104 to 1011 copies of decorin gene cloned into the
pTRUF11 vector. The DNA probe was prepared by digesting 5 g of
decorin plasmid with the NotI restriction enzyme and labeling 1 g of
isolated decorin fragment with digoxigenin (DIG)-labeled UTP (DIG
starter Kit II; Roche Applied Science). Two microliters of the standard
as well as the DNA isolated from corneal tissues was denatured by
alkali and heat treatment. Denatured DNA samples were blotted onto
nylon membrane with a slot-blot apparatus (Bio-Rad Laboratories, Her-
cules, CA) and were UV cross-linked. The membrane was hybridized
with 300 ng of DIG-labeled probe overnight at 30°C, followed by
incubation in 1:5000 anti-DIG-AP antibody. Chemiluminescent detec-
tion was used according to the vendor’s instructions (Roche Applied
Science), and the membranes were exposed to x-ray film. Image J 1.38
X image analysis software was used to determine the number of
delivered gene copies in samples by measuring dot intensities in the
samples and comparing the data with standards (Image J 1.38X devel-
oped by Wayne Rasband, National Institutes of Health, Bethesda, MD;
available at http://rsb.info.nih.gov/ij/index.html).
Statistical Analyses
The results of corneal haze grading, SMA quantification and collagen
fibril diameter were expressed as the mean  SEM. Statistical analysis
was performed with Student’s t-test or the Wilcoxon rank sum test.




Figure 1 shows slit lamp- and stereo-biomicroscopy images
depicting corneal haze in no-decorin-delivered (control) and
decorin-delivered rabbit corneas. The PRK-treated rabbit eyes
that received AAV5-gfp vector showed a strong fibrotic re-
sponse in the cornea as evident from the cloudiness (Figs. 1A,
1B). The PRK-treated rabbit eyes that received AAV5-dcn vec-
tor showed a substantial decrease in corneal cloudiness (Figs.
1C, 1D). The PRK- or AAV5-untreated negative control rabbit
corneas showed no corneal haze (Fig. 1E). The quantification
of haze inhibition after decorin gene therapy was performed in
a blinded fashion by three researchers. Figure 1F shows the
mean haze score in decorin-delivered and no-decorin-delivered
rabbit corneas observed 4 weeks after vector application. The
no-decorin-delivered rabbit corneas showed an average haze
score of 3  0.4, whereas decorin-delivered rabbit corneas
showed a significantly (P  0.01) lower corneal haze score of
1.3  0.3 (Fig. 1F). Optical coherence tomography did not
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detect any significant difference in corneal thickness among
the naïve , no-decorin-delivered, and decorin-delivered rabbit
corneas (data not shown). These findings suggest that AAV5-
mediated decorin gene therapy is highly efficient in preventing
corneal fibrosis and appears safe for the rabbit cornea.
Immunohistochemical Determination of
Corneal Fibrosis
Myofibroblast formation is a hallmark of corneal fibrosis and is
characterized by the expression of cytoskeletal proteins, such
as SMA, F-actin, and fibronectin. We evaluated the inhibitory
effects of decorin gene delivery on corneal fibrosis by immu-
nostaining rabbit corneal tissues for those three proteins. Fig-
ure 2 shows the immunostaining for SMA (Figs. 2A, 2B),
F-actin (Figs. 2C, 2D), and fibronectin (Figs. 2E, 2F) in decorin-
delivered and no-decorin-delivered rabbit corneas. The rabbit
corneas subjected to PRK without AAV5-dcn vector treatment
showed intense SMA immunostaining in the anterior stroma
confirming the presence of myofibroblasts and development of
haze (Fig. 2A). Conversely, decorin-delivered rabbit corneas
showed a significant decrease in SMA expression (Fig. 2B),
suggesting that AAV5-mediated decorin gene therapy effec-
tively attenuates fibrosis in the rabbit cornea in vivo. The
antifibrotic effects of decorin gene therapy were revalidated by
F-actin (Figs. 2C, 2D) and fibronectin (Figs. 2E, 2F) immunocy-
tochemistry. Both, additional tested fibrotic parameters
showed similar levels of decrease as noted for SMA, providing
further support that AAV5-delivered decorin in the stroma
modulates ECM proteins and wound healing and inhibits scar
formation in the rabbit cornea. Phalloidin staining also de-
tected the filamentous actin of the epithelial borders (Figs. 2C,
2D) that used anti-mouse monoclonal SMA antibody was able
to recognize feebly (Figs. 2A, 2B). The naïve rabbit corneas did
not show any positive staining of tested antigens in the stroma
(data not shown).
The quantification of SMA immunostaining in the rabbit
corneas subjected to PRK with AAV-dcn or AAV-gfp treatment
is shown in Figure 3. As evident from the data shown in Figure 3,
AAV5-mediated decorin gene therapy given by a single 2-min-
ute topical application caused a statistically significant de-
crease in SMA (59%; P  0.001). The digital quantification of
F-actin and fibronectin immunocytochemistry data showed a
significant decrease in F-actin (72%; P  0.001) and fibronectin
(64%; P  0.01) expression in the rabbit cornea in vivo.
Immunoblot Quantification of Corneal Fibrosis
The efficacy of AAV5-mediated decorin gene therapy on cor-
neal fibrosis was also examined by SMA immunoblot analysis.
Figure 4 shows results of SMA Western blot performed with
protein lysates of the decorin-delivered and undelivered rabbit
corneas collected 4 weeks after PRK (haze is at its peak at this
time point). The quantification of immunoblot data with Im-
age-J demonstrated a statistically significant reduction in the
expression of SMA in decorin-delivered corneal samples
(67%; P  0.01) compared to no-decorin-delivered control
corneal samples (Fig. 4). The -actin of the same intensity band
in each lane confirmed equal loading of protein samples. These
data further indicate that AAV5-mediated decorin gene therapy
is significantly effective in reducing corneal fibrosis in a rabbit
model.
FIGURE 1. Representative stereomicroscopy (A, C, E) and slit lamp (B, D) biomicroscopy images showing haze levels in no-decorin-delivered
control (A, B) and decorin-delivered (C, D) rabbit corneas. Haze was produced with PRK surgery, AAV5 viral titer (6.5  1012 g/mL) was applied
immediately to the cornea for 2 minutes after PRK, and corneal tissues were imaged 4 weeks after PRK (the time at which peak in haze is reported).
(F) Quantification of corneal haze. Significantly less haze (P  0.01) was observed in decorin-delivered corneas than in no-decorin-delivered
corneas. No haze was observed in the contralateral naïve rabbit corneas (E). dcn, decorin.
4836 Mohan et al. IOVS, June 2011, Vol. 52, No. 7
Effects of AAV5-Mediated Decorin Gene Transfer
on In Vivo Cytotoxicity and Immunity
The CD11b (activated granulocytes marker) and F4/80 (mac-
rophage marker) immunostaining and TUNEL assay were used
to analyze the immunogenicity and cytotoxicity of the used
AAV5 vector for corneal decorin gene therapy. The anti-mouse
CD11b and F4/80 antibodies known to cross-react with rabbit
antigen were used for the study.36,37 Furthermore, to ensure
their reactivity to the rabbit corneal tissues, alkali burn rabbit
corneas collected 4 hours after 30 seconds of 1 M sodium
hydroxide application on the cornea were used as a positive
control. Figure 5 shows results of CD11b and F4/80 immuno-
staining detected in the alkali-burn (Fig. 5, left), no-decorin-
delivered (Fig. 5, middle), and decorin-delivered (Fig. 5, right)
rabbit corneas. The positive control alkali-burn corneal sec-
tions showed numerous CD11b and F4/80 cells, confirming
that used antibodies recognize rabbit antigens. The naïve (data
not shown), no-decorin-delivered (Fig. 5, middle), and decorin-
delivered (Fig. 5, right) rabbit corneal sections showed two to
six CD11b or F4/80 cells. The detection of occasional and
statistically insignificant CD11b or F4/80 cells in the naïve,
no-decorin-delivered, and decorin-delivered rabbit corneas sug-
gests that AAV5-delivered decorin gene therapy does not in-
duce significant immune response in the cornea.
The in vivo cytotoxicity of AAV5-mediated decorin gene
therapy for the cornea was analyzed by TUNEL assay. Figure 6
shows the results of TUNEL staining in rabbit corneas. Detec-
tion of one to four TUNEL cells (shown in red) in the stroma
FIGURE 2. Effect of AAV5-mediated
decorin gene delivery on markers of
corneal fibrosis, as detected by im-
munostaining in rabbit corneal tis-
sue. Immunohistochemistry showing
levels of SMA (A, B), F-actin (C, D),
and fibronectin (E, F) in no-decorin-
delivered control and decorin-deliv-
ered rabbit corneal tissue, collected
at 4 weeks after PRK-induced corneal
fibrosis. Blue: DAPI-stained nuclei;
green: SMA staining; red: F-actin
and fibronectin staining. Decorin-
treated corneas showed significant
decreases in SMA (P  0.001) and
notable decreases in F-actin and fi-
bronectin levels in the stroma com-
pared with that in control corneas.
Scale bar, 100 m.
FIGURE 3. The effect of AAV5-mediated decorin gene therapy on
fibrosis in rabbit corneal tissues quantified by counting SMA-positive
cells at 400 magnification. Decorin treatment significantly (P 
0.001) decreased SMA-positive cells.
FIGURE 4. Western blot analysis for SMA, to detect the effect of
AAV5-mediated decorin gene therapy on fibrosis in rabbit corneas. A
significant (75%–86%) decrease in the expression of SMA was de-
tected in decorin-delivered corneas compared with control corneas,
suggesting that AAV5-mediated decorin gene therapy is highly efficient
in treating corneal fibrosis. -Actin was used to confirm equal loading
of protein in each well and to normalize the data.
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of the naïve (data not shown), no-decorin-delivered (Fig. 6A),
and decorin-delivered (Fig. 6B) rabbit corneas suggests that the
AAV5 vector is noncytotoxic to keratocytes. The 6 to 10
TUNEL cells observed in the corneal epithelium were due to
its replenishment. The presence of similar number of DAPI-
stained nuclei in no-decorin-delivered (Fig. 6, left) and decorin-
delivered (Fig. 6, right) rabbit corneas also allows us to infer
that optimized AAV-based decorin delivery into stroma does
not alter keratocyte population. These results suggest that the
defined gene transfer modality is safe for in vivo corneal gene
therapy.
Effects of AAV5-Mediated Decorin Gene Transfer
on Corneal Collagen Fibrils
Decorin is known to bind to collagen and regulate fibrillogen-
esis. Collagen fibril diameter and arrangement in the cornea
play an important role in corneal transparency. Thus, we used
transmission electron microscopy to determine whether
decorin gene therapy affects collagen fibril diameter and/or
arrangement in the cornea. Figure 7 shows the diameter and
arrangement of collagen fibrils in no-decorin-delivered (Fig.
7A) and decorin-delivered (Fig. 7B) rabbit corneas. The lack of
a significant difference between the collagen fibril arrange-
ment and diameter in the decorin-delivered and no-decorin-
delivered rabbit corneas suggests that AAV5-delivered decorin
to the stroma did not jeopardize the geometric arrangement of
the collagen fibrils. The quantification of collagen fibril diam-
eter data shown in Figure 7C did not detect any significant
differences between the corneas of the two groups.
Determination of Delivered Decorin Gene Copies
with AAV5
To confirm the delivery of the decorin gene after a single
topical application of AAV5-dcn on the rabbit cornea, we
determined the decorin gene copy number by using a slot-blot
assay. Figure 8 shows the gene copy number delivered in the
rabbit corneas by AAV5 selected for this study. Densitometric
quantification of slot blotting data revealed delivery of an
average of 109 genomic copies of decorin by AAV5 in rabbit
cornea.
DISCUSSION
We previously identified the AAV serotypes efficient for deliv-
ering genes to the cornea in vivo; optimized minimally invasive
delivery techniques for administering vectors preferentially
into keratocytes or endothelium in vivo; and using a combi-
nation of vector and delivery technique, defined tissue-
selective targeted gene therapy approaches for treating cor-
neal disorders and dystrophies.8 –12,16 In this study, for the
first time, we report that tissue-selective targeted decorin
gene delivery in the cornea with AAV5 significantly retarded
corneal fibrosis in vivo in a well-established laser-based ex-
FIGURE 5. Effect of AAV5-decorin gene therapy on immune response in rabbit corneas using CD11b and F4/80 immunocytochemistry. The lack
of a significant difference in the presence of CD11b- and F4/80-stained cells in the stroma of no-decorin-delivered and decorin-delivered rabbit
corneas suggests that AAV5-mediated decorin gene therapy does not induce an immune response in the cornea. Blue: DAPI-stained nuclei; red:
CD11b or F4/80 stained cells. Alkali-burned rabbit corneal tissue sections at 4 hours were used as the positive control. Scale bar, 100 m.
FIGURE 6. Effect of AAV5-decorin
gene delivery on rabbit corneal toxicity
tested with TUNEL assay. The low num-
ber of TUNEL cells (n  2–5) in the
stroma of no-decorin-delivered control
(A) and decorin-delivered (B) rabbit cor-
neal sections, the comparable number of
TUNEL cells in the epithelium, and no
change in overall keratocyte density in
the stroma determined with DAPI nu-
clei suggests that decorin gene therapy is
noncytotoxic and safe for the cornea.
Red: TUNEL cells; blue: DAPI nuclei.
Scale bar, 100 m.
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perimental rabbit corneal scarring model. In addition, we
report that AAV5-mediated gene therapy was safe for the
cornea, as visual and slit lamp clinical eye examinations did
not detect inflammation, redness, opacity, mucous, or other
discharges in the rabbit eye, and optical coherence tomog-
raphy imaging did not find any distortion in rabbit corneal
thickness or curvature.
Decorin gene transfer has been reported to significantly
attenuate fibrosis in many nonocular tissues such as heart,
kidneys, and lungs.25–32 Recently, we reported significant in-
hibition of TGF-induced transformation of human and rabbit
corneal fibroblasts to myofibroblasts and profibrogenic genes
with decorin gene transfer.33 Decorin is a small, leucine-rich
proteoglycan that has been shown to play an important role in the
regulation of various ocular and nonocular diseases.24,38–40 In the
cornea, decorin is expressed in the stroma and contributes to
the maintenance of clarity and structural integrity of the cor-
neal stroma required for normal vision.4,24,41 In addition to
decorin, other proteoglycans such as biglycan, fibromodulin,
mimecan, keratocan, and lumican are expressed in the cornea
and have been shown to play a role in corneal healing and
homeostasis.42–44 Recently, we investigated the levels and lo-
calization of decorin and TGF in normal and PRK-injured
rabbit corneas at various time points, to better understand the
function of decorin in the cornea.20,24 The results of these
studies revealed that decorin plays an important role in pre-
venting scar formation in the cornea by hindering TGF activ-
ity. Decorin, an endogenous inhibitor of TGF, has been
shown to regulate the TGF signal transduction pathway
through its interaction with low-density lipoprotein receptor–
related protein-1 and the decorin endocytic receptor.24,40 Fur-
thermore, decorin modulates signaling of epidermal growth
factor receptors (EGFR) and insulin-like growth factor-I and its
receptor.24,40 Based on the fact the decorin binds to all three
isoforms of TGF with equal affinity and TGF is a key mod-
ulator of corneal fibrosis, we postulate that observed antifi-
brotic effects of decorin gene therapy in rabbit cornea in vivo
are due to modulation of TGF signaling by decorin. Future
studies will test this hypothesis to gain understanding of the
molecular mechanism associated with corneal scar inhibition
by decorin.
Numerous viral and nonviral vectors have been tested for
delivering therapeutic genes in the cornea. However, AAV
vectors have been found most suitable for transducing slow/no
dividing corneal endothelium or keratocytes.8–12 Our recent
studies found AAV serotypes 5, 8, and 9 highly efficient in
transducing rodent and rabbit corneas in vivo with no major
side effects. In this study, AAV serotype 5 was used for decorin
gene delivery because toxicity and safety of AAV5 have been
extensively investigated in our laboratory for the cornea during
the optimization of targeted gene therapy approaches for the
cornea. Another major challenge in the development of tissue-
targeted gene therapy for the cornea is the unavailability of a
cornea-tissue specific promoter that is not leaky. The studies
from several research groups showed promise in the identifi-
cation of nonleaky cornea cell–specific promoter.45–47 To ad-
dress this limitation, we postulated a few years ago that admin-
FIGURE 7. Effect of decorin gene
therapy on collagen fibril diameter
determined by transmission electron
microscopy of no-decorin-delivered
control (A) and decorin-delivered (B)
rabbit corneas. (C) Quantification of
collagen fibril diameter in nanome-
ters. No significant difference in the
collagen fibril diameter was detected
between control and decorin-deliv-
ered rabbit corneas. This result sug-
gests that AAV5-delivered decorin
did not alter the collagen fibril status
in the rabbit cornea. dcn, decorin.
FIGURE 8. Slot-blot analysis showing the decorin gene copy number
delivered by the AAV5 vector to the rabbit cornea. Densitometric
analysis detected 109 copies of the decorin gene delivered by the
vector to the rabbit corneas,. Left lane: the pTRUF11-dcn plasmid DNA
blotted at different concentrations; right lane: corneal DNA samples
isolated from two animals that received AAV5-dcn.
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istration of vector with minimally invasive surgical techniques
can be used for developing targeted gene therapy for corneal
diseases because of the physical accessibility of corneal tissue.
Thus, several minimally invasive simple surgical techniques
were optimized to administer gene transfer vectors into rabbit
and rodent stromal keratocytes or corneal endothelial cells.18
Indeed, introduction of efficient vectors via optimized delivery
techniques permitted tissue- and site-selective targeted gene
delivery into keratocytes or endothelium.19 In our optimized
corneal gene therapy approaches, targeted gene delivery in the
cornea is predominantly dependent on vector delivery tech-
niques.
The safety and toxicity of the vector to the patient and the
environment are major concerns with gene-based therapy.
Many viral and nonviral gene transfer methods, although effi-
cient for delivering genes to the cornea, cannot be used for
patients, because of their toxicity and/or lack of safety. In this
study, we used AAV for introducing the decorin gene into the
rabbit stroma, because of its nonpathogenicity, low immuno-
genicity, and safety. Eyes exposed to the AAV5 vector did not
show significant keratocyte apoptosis, when examined by
TUNEL assay, or infiltration of immune cells in the stroma,
when examined with CD11b or F4/80 immunocytochemistry,
suggesting that AAV5-mediated decorin gene therapy is noncy-
totoxic and safe for the cornea. Decorin interacts with collagen
to modulate collagen fibril organization, cross-linking, and deg-
radation.38–40 In vitro studies have demonstrated that decorin
could restrict fibrillar collagens to a thinner and homogeneous
diameter whereas in vivo studies of decorin knockout mice de-
tected larger diameter collagen fibrils in skin tissues.24,38–40,48
These reports raised a possibility that decorin gene delivery
could affect collagen fibril organization in the cornea. We
postulated that AAV-mediated decorin gene therapy does not
jeopardize corneal collagens, based on the fact that it would
require decorin interaction with collagen and de novo collagen
synthesis, and collagens in the cornea have an extremely low
turnover. No significant differences in collagen fibril diameter
and arrangement in decorin-delivered and no-decorin-delivered
rabbit corneas observed with transmission electron microcopy
supported our hypothesis. Furthermore, the optical coherence
tomography biomicroscopy performed in rabbit eyes provided
additional support to our hypothesis as no significant change in
corneal thickness up to 4 weeks was observed among the
naïve, no-decorin-delivered, and decorin-delivered rabbit cor-
neas. Our ongoing corneal gene transfer studies performed in
the rodent model show that the AAV-delivered transgene in the
stroma continues to be expressed up to 11 months and possi-
bly more (Mohan et al. unpublished data, 2011). This raises the
question of whether long-term retention of the AAV-decorin
gene in the stroma has any adverse effects on corneal function?
Longer duration studies are needed to address such a relevant
question. It is worth mentioning that keratocytes in the stroma
are slow-dividing cells and tend to stay in the stroma without
proliferation under normal or non–wound-healing conditions.
Our future studies will examine the effects of long-term ex-
pression of AAV-mediated decorin gene transfer in the stroma
on corneal homeostasis and wound healing.
In summary, for the first time, this study demonstrates
significant inhibition of corneal fibrosis in the rabbit cornea by
AAV5-mediated, tissue-targeted gene therapy, with no visual
side effects. Furthermore, results of this study support our
hypothesis that tissue-selective, targeted delivery of therapeu-
tic genes to the stroma with defined gene therapy approaches
can effectively cure ocular surface diseases without causing
significant side effects.
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